Dear Interested NAIC Regulators, the Long-Term Care Insurance (LTCI) Reduced Benefit Options (EX) Subgroup, Senior Issues (B) Task Force, Health Actuarial (B) Task Force, and Interested Parties:

This letter is in response to the draft long term care insurance (LTCI) wellness program document circulated on 7/22/2021. We are a group of physicians who specialize in cognitive and neurological issues in adults. Many of our patients require home care, assisted living, or long-term care eventually in their lifetime. LTCI has been beneficial for our patients that need custodial care.

Regarding the cognitive wellness initiatives specifically related to “Technological solutions aimed at improvements in cognitive impairment prevention and early diagnosis”, we have the following concerns:

- Insurance carriers are implementing various digital technologies such as wearables, eye-tracking, and other digital biomarkers as the sole means to flag patients with cognitive risk. These technologies are rapidly evolving, experimental and, at most, should be considered data points that are used for decision support. We highly recommend that insurance carriers urge their members to see their physician for a proper cognitive risk evaluation.

- Research from the Alzheimer’s Association has demonstrated approximately 50% of cognitive impairment cases are undiagnosed. New cognitive wellness programs in LTCI that identify patients for cognitive risk could potentially do so before a physician has diagnosed or disclosed the medical condition to the patient. This brings up a variety of legal risks to both the insurance carrier, cognitive wellness coaches, and for the patient.

- As part of cognitive impairment guidelines from the American Academy of Neurology, there is bloodwork and imaging to do as part of the medical workup, as well as ruling out common conditions that “mimic” cognitive impairment (i.e., delirium, vitamin deficiencies, depression). This process is not being verified by insurance carriers or cognitive wellness programs. This gap in care may result in a high number of patients incorrectly flagged as having cognitive risk (false positives). This may also have downstream financial implications for patients through increased insurance premiums.
• Social workers and nurses should not be flagging, diagnosing, or telling patients they have cognitive impairment without a proper medical evaluation and workup by their physician using evidence-based clinical practice guidelines. This gap in care is currently underway at LTCI third-party administrators (during face-to-face assessments) and in internal claims processing workflows during chronic illness verification and the adjudication process. In 2020, an independent external medical advisory task force found 20-30% of potential claims to have a possible “treatable” condition to their cognitive impairment (delirium, depression, vitamin deficiencies etc.). These patients may have received an incorrect label of irreversible cognitive impairment.

• There are ethical and legal consequences to consider in telling someone they are at risk for dementia or have cognitive impairment before a physician does so. Some states require clinicians to report the patient’s medical condition to the DMV or alert banks regarding mental capacity.

As advocates for patient safety and care representing several U.S territories, we are concerned that these issues will put our patients in harm rather than benefiting them. We suggest to the committee that they seek the advice from an external independent medical advisory board before implementing any nationally approved cognitive wellness programs.

Yours respectfully,

Anitha Rao MD, MA
Board-Certified Neurologist
Founder and CEO Neurocern
Clinical Associate Professor, University of Toledo
Department of Neurology

Philip Tipton, MD
Assistant Professor
Mayo Clinic Florida
Behavioral Neurology & Movement Disorders divisions
Diplomat ABPN
Diplomat of UCNS Behavioral Neurology & Neuropsychiatry

Uma Menon, MD, MBA.
Chief of Neurology Division
Morehouse School of Medicine
Nicole Rosendale, MD | she/her/hers
Assistant Professor of Neurology
Neurohospitalist Division
University of California San Francisco
Director, SFGH Neurology Inpatient Services

Jerome Lisk, M.D., FAAN
Board Certified & Fellowship Trained in Movement Disorders
MD Neurology Director of Movement Disorders Denton/Flower Mound, Tx.
3120 Medpark Dr. Suite 100, Denton, Texas 76208

Danielle Goldfarb, MD
Assistant Professor of Neurology and Psychiatry
University of Arizona College of Medicine
Banner Sun Health Research Institute
Sun City, AZ

Amy Guzik, MD
Associate Professor, Neurology
Wake Forest Baptist Medical Center

David Beversdorf, MD, FAAN, FANA, ABPN Diplomate, UCNS BNNP Ceritified
Professor of Radiology, Neurology, and Psychological Sciences
William and Nancy Thompson Endowed Chair in Radiology
University of Missouri

Sameh Morkous, MD, FAAP, FAAN,FAASM, ABPN Diplomate
Chief, Pediatric Neurology Section
Medical Director, Lehigh Valley Health Network Pediatric Sleep Disorders Center
Clinical Professor, Philadelphia College of Osteopathic Medicine (PCOM) & DeSales University
Associate Professor, collaborative with Morsani College of Medicine at the University of South Florida

Smita Patel DO
Founder and Medical Director
Integrative Neurology and Sleep
iNeuro Institute
Des Plaines, IL

Teryn Clarke, M.D
Board-Certified Neurologist
Clarke Neurology
Newport Beach, California
Daniel C. Potts, MD, FAAN  
Attending Neurologist, Tuscaloosa VA Medical Center  
Founder and President, Cognitive Dynamics Foundation  
Adjunct Faculty, College of Community Health Sciences & Honors College  
The University of Alabama  
Adjunct Faculty, The University of South Alabama College of Medicine  
Affiliate, Alabama Research Institute on Aging, The University of Alabama

Nancy B. Isenberg, MD, MPH, FAAN DipABLM  
Medical Director, Center for Healthy Aging/Neurology  
Clinical Associate Professor, Neurology, University of Washington  
Swedish Neuroscience Institute  
7320 216th Street SW  
Edmonds, WA 98026

Gorazd Stokin, MD, PhD, FAAN  
Research collaborator, Mayo Clinic, Rochester, USA

Anthony Davis, M.D.  
Davis Neurology  
Russellville, AR  
Diplomat ABPN

Harris A. Eyre MBBS PhD  
Chief Medical Officer, PRODEO  
Co-founder, PRODEO Institute  
San Francisco, CA

Sarah Maulden, MD, MS  
Board Certified in Neurology and Clinical Informatics  
Assistant Professor of Neurology, University of Utah, and Salt Lake VA Medical Center  
Salt Lake City, Utah

Haleh Nekoorad-Long MD  
Cascade Behavioral Health  
Geriatric Psychiatry  
Seattle, WA 98116
Sylvia E. Josephy, MD, MSc
Behavioral Neurology and Neuropsychiatry Fellow
Massachusetts General Hospital
Boston, Massachusetts

Tara Kimbason, M.D.
Board Certified Neurologist
Tallahassee Memorial Healthcare
Tallahassee, FL
Diplomat ABPN

Alan Finkel MD
Board-Certified Neurologist
Carolina Headache Institute
Durham, North Carolina

Allen Gee MD, PhD, FAAN
Board-Certified Neurologist
Frontier Neurohealth
Cody, Wyoming

Benzi Kluger MD, MS
Board-Certified Neurologist
Chief and Founder Palliative Care
University of Colorado
Aurora, Colorado

Susan Douglas MD, JD
Board-Certified Neurologist
University of California Los Angeles
Los Angeles, California

Benjamin Miller MD
Board-Certified Neurologist
University of Minnesota

Elizabeth Barber PhD
Barber Innovation LLC
Winfield, Illinois